NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 44.530
- -1.010-2.22%
Close Mar 4 16:00 ET
- 42.610
- -1.920-4.31%
Pre 04:02 ET
3.55BMarket Cap-11.87P/E (TTM)
45.650High43.630Low1.33MVolume44.970Open45.540Pre Close59.51MTurnover2.02%Turnover RatioLossP/E (Static)79.62MShares58.40052wk High4.73P/B2.93BFloat Cap17.86052wk Low--Dividend TTM65.77MShs Float58.400Historical High--Div YieldTTM4.44%Amplitude7.520Historical Low44.714Avg Price1Lot Size
Akero Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -58.29%-230.11M | -37.97%-67.09M | -41.64%-70.42M | -156.61%-57.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M |
| Net income from continuing operations | -66.09%-252.06M | -26.89%-70.02M | -83.33%-72.71M | -80.12%-55.99M | -106.51%-53.34M | -35.46%-151.76M | -139.33%-55.19M | -11.58%-39.66M | -13.43%-31.08M | 0.76%-25.83M |
| Operating gains losses | 601.41%498K | -352.38%-95K | 6,150.00%125K | 86.11%-10K | 195.06%478K | -74.64%71K | -107.98%-21K | -95.12%2K | -380.00%-72K | 1,900.00%162K |
| Depreciation and amortization | -37.93%18K | 650.00%15K | -80.00%1K | -90.91%1K | -90.91%1K | -32.56%29K | -80.00%2K | -54.55%5K | 0.00%11K | 0.00%11K |
| Other non cash items | 82.43%1.86M | 32.78%239K | 30.29%228K | 616.47%1.22M | -64.78%174K | 142.04%1.02M | 20.81%180K | 17.45%175K | 142.86%170K | 832.08%494K |
| Change In working capital | 144.95%3M | -135.36%-1.39M | 85.81%-1.8M | -233.46%-6.88M | 529.53%13.08M | -49.59%-6.67M | 158.48%3.93M | -1,152.41%-12.71M | 42.45%5.16M | -774.71%-3.04M |
| -Change in prepaid assets | -157.42%-17.35M | -80.59%2.15M | 21.01%-13.76M | -6,168.42%-8.07M | 562.77%2.34M | -419.13%-6.74M | 2,128.07%11.05M | -3,356.26%-17.42M | 121.88%133K | -118.50%-505K |
| -Change in payables and accrued expense | 6,746.18%20.61M | 50.94%-3.47M | 152.11%12.02M | -75.49%1.25M | 531.48%10.8M | 104.73%301K | -15.50%-7.07M | 418.36%4.77M | 19.19%5.1M | 17.37%-2.5M |
| -Change in other current liabilities | -12.12%-259K | -13.33%-68K | -10.00%-66K | 16.00%-63K | -72.22%-62K | -12.14%-231K | -9.09%-60K | -15.38%-60K | -50.00%-75K | 26.53%-36K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -58.29%-230.11M | -37.97%-67.09M | -41.64%-70.42M | -156.61%-57.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 50.94%-109.71M | 19.44%15.27M | 158.13%73.07M | -99.45%-255.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M |
| Net intangibles purchase and sale | ---999K | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net investment purchase and sale | 51.39%-108.71M | 19.44%15.27M | 158.13%73.07M | -98.67%-254.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 50.94%-109.71M | 19.44%15.27M | 158.13%73.07M | -99.45%-255.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 26.19%445.85M | 15,037.65%75.99M | 280.52%3.07M | -100.04%-150K | 2,321.55%366.94M | 38.21%353.32M | -81.56%502K | -99.63%806K | 865.84%336.86M | 11,379.55%15.15M |
| Net issuance payments of debt | -33.33%10M | --0 | --0 | --0 | -33.33%10M | 50.00%15M | --0 | --0 | --0 | --15M |
| Net common stock issuance | 26.13%423.08M | --67.64M | --0 | --0 | --355.44M | 39.07%335.43M | --0 | --0 | --335.43M | --0 |
| Proceeds from stock option exercised by employees | 271.53%13.61M | 1,472.61%8.38M | 288.46%3.13M | -82.49%327K | 287.94%1.77M | -30.83%3.66M | -81.55%533K | -61.29%806K | 949.44%1.87M | 210.20%456K |
| Net other financing activities | -8.76%-844K | 6.45%-29K | ---64K | -7.92%-477K | 9.57%-274K | 10.19%-776K | 81.33%-31K | --0 | -46.84%-442K | -1,920.00%-303K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 26.19%445.85M | 15,037.65%75.99M | 280.52%3.07M | -100.04%-150K | 2,321.55%366.94M | 38.21%353.32M | -81.56%502K | -99.63%806K | 865.84%336.86M | 11,379.55%15.15M |
| Net cash flow | ||||||||||
| Beginning cash position | -6.27%234.21M | 17.26%316.07M | -30.12%310.36M | 141.81%623.85M | -6.27%234.21M | 65.93%249.88M | -27.95%269.55M | 149.76%444.16M | 71.31%257.99M | 65.93%249.88M |
| Current changes in cash | 776.48%106.03M | 168.40%24.17M | 103.27%5.71M | -268.40%-313.5M | 4,703.93%389.65M | -115.79%-15.67M | 71.55%-35.34M | -188.96%-174.61M | 583.47%186.16M | 135,083.33%8.11M |
| End cash Position | 45.27%340.24M | 45.27%340.24M | 17.26%316.07M | -30.12%310.36M | 141.81%623.85M | -6.27%234.21M | -6.27%234.21M | -27.95%269.55M | 149.76%444.16M | 71.31%257.99M |
| Free cash flow | -58.98%-231.11M | -37.97%-67.09M | -41.64%-70.42M | -161.07%-58.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |